By KYIV. Dec 9 (Interfax-Ukraine) – The State Enterprise Medical Procurement of Ukraine has carried out the first centralized procurement of Risdiplam by Roche, a medication for treatment of spinal muscular atrophy (SMA), using the mechanism of Managed Access Agreements (MAAs).
"Thanks to high-quality communication, we have managed to receive favorable conditions and, for the first time in the history of our country, centrally provide patients suffering from this complex disease with free treatment," Acting Director General of Medical Procurement of Ukraine Edem Adamanov said.
According to the information collected from hospitals through the MedData system, currently there are 111 children with SMA in Ukraine.
In 2023, for the first time in the history of the country, patients with SMA will receive treatment with this medication for free.
The company said that one bottle of Risdiplam costs more than UAH 250,000 at Ukrainian pharmacies. This is the only oral medication for SMA that can be used by a patient at home.
SMA is a rare neuromuscular disease that causes limb atrophy and death.
Medical Procurement of Ukraine also said that the list of medications, which will be procured under the MAAs, has been approved by the Cabinet of Ministers of Ukraine on December 9.
